8-K: AIM ImmunoTech Enters $3 Million Equity Distribution Agreement with Maxim Group LLC

AIM ImmunoTech Inc. has entered into an equity distribution agreement with Maxim Group LLC to sell up to $3 million of its common stock through an at-the-market offering program.

Summary

• AIM ImmunoTech Inc. has entered into an Equity Distribution Agreement with Maxim Group LLC to sell shares of its common stock for an aggregate offering price of up to $3,000,000 through an at-the-market (ATM) offering program.
• Maxim Group LLC will act as the exclusive sales agent for this offering.
• Due to the limitations of General Instruction I.B.6 of Form S-3, the Company can initially only sell $663,329.
• The Company filed a universal shelf registration statement on Form S-3, which includes a prospectus relating to the ATM Offering, with the SEC.
• Once the SEC declares the Registration Statement effective, the Company will be able to offer and sell Shares in the ATM Offering under the Prospectus through Maxim pursuant to the Sales Agreement.
• Maxim will make sales using commercially reasonable efforts consistent with its normal trading and sales practices.
• The compensation payable to Maxim for sales of Shares will be 3.0% of the gross proceeds for any Shares sold.
• The Company has agreed to reimburse Maxim for certain expenses it incurs in the performance of its obligations up to a maximum of $50,000, and $5,000 per quarter thereafter.
• The Sales Agreement may be terminated by either the Company or Maxim with fifteen (15) days written notice.
• The ATM Offering will terminate upon the earlier of (i) the sale of Shares under the Distribution Agreement having an aggregate offering price of $3 million, (ii) 24 months from the date of the Sales Agreement, or (iii) the termination of the Sales Agreement by either the Company or Maxim upon the provision of fifteen (15) days written notice.
• Sales of Shares under the ATM Offering shall not exceed $3 million, unless and until the Company files an amended or new Prospectus Supplement.
• The Company intends to use the net proceeds from the sale of Shares for working capital and general corporate purposes.

Sentiment

Score: 6

Explanation: The announcement is neutral. It outlines a financial transaction that could be beneficial for the company's working capital but also carries the risk of dilution for existing shareholders.

Positives

• The agreement provides AIM ImmunoTech with a flexible way to raise capital as needed.
• The company intends to use the net proceeds for working capital and general corporate purposes.

Negatives

• The offering could dilute existing shareholders' ownership.
• The company can initially only sell $663,329 due to the limitations of General Instruction I.B.6 of Form S-3.

Risks

• The company may not be able to sell all of the shares it intends to offer.
• The market price of the company's stock could decline as a result of the offering.
• There is no guarantee that the SEC will declare the Registration Statement effective.

Future Outlook

The Company intends to use the net proceeds from the sale of Shares for working capital and general corporate purposes.

Industry Context

At-the-market offerings are a common way for small-cap companies to raise capital. They allow companies to sell shares gradually into the market, which can help to minimize dilution and avoid large price swings.

Comparison to Industry Standards

• Comparable companies that have used ATM offerings include Sorrento Therapeutics, which announced a $500 million ATM offering in 2020, and Cassava Sciences, which announced a $200 million ATM offering in 2021.
• The 3.0% commission is within the typical range for ATM offerings.

Stakeholder Impact

• Shareholders may experience dilution of their ownership.
• The company may be able to invest in growth initiatives with the raised capital.
• Maxim Group LLC will receive fees for its services.

Next Steps

• The Company needs to have the Registration Statement declared effective by the SEC.
• Maxim Group LLC will then begin selling shares of the Company's common stock into the market.

Key Dates

Keywords

equity distribution agreement, at-the-market offering, common stock, AIM ImmunoTech, Maxim Group LLC, capital raise